---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-051276"
form_type: "8-K"
ticker: "RNLXY"
cik: "0001811115"
company_name: "Renalytix plc"
filed_at: "2023-10-03T23:59:59+00:00"
generated_at: "2026-06-10T05:36:12.141752+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CMS sets Medicare price for Renalytix's kidneyintelX.dkd test at $950, effective Jan 2024

## Summary
- CMS published price for FDA-authorized kidneyintelX.dkd test on national Clinical Lab Fee Schedule at $950.
- Pricing effective Jan 1, 2024 and maintained for a minimum of three years.
- AMA panel recommended a new CPT code to differentiate kidneyintelX.dkd from the original LDT, triggering the pricing review.
- Company states the CMS action affirms KidneyIntelX platform value and aids in expanding insurance coverage.

## SEC filing metadata
- accession: 0000950170-23-051276
- form_type: 8-K
- ticker: RNLXY
- cik: 0001811115
- company_name: Renalytix plc
- filed_at: 2023-10-03T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811115/000095017023051276/0000950170-23-051276-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811115/000095017023051276/rnlx-20231003.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-051276
- JSON: https://secwatch.observer/filing/0000950170-23-051276.json
- Plain text: https://secwatch.observer/filing/0000950170-23-051276.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.